NASDAQ:BOLD - Audentes Therapeutics Stock Price, News, & Analysis

$38.80
+0.90 (+2.37 %)
(As of 07/22/2019 04:00 PM ET)
Today's Range
$38.21
Now: $38.80
$39.79
50-Day Range
$33.75
MA: $37.61
$40.52
52-Week Range
$17.95
Now: $38.80
$42.04
Volume314,371 shs
Average Volume536,511 shs
Market Capitalization$1.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BOLD
CUSIPN/A
Phone415-818-1001

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($7.48) per share

Profitability

Net Income$-128,820,000.00

Miscellaneous

Employees207
Market Cap$1.72 billion
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.

Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) announced its earnings results on Tuesday, May, 7th. The biotechnology company reported ($1.13) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.90) by $0.23. During the same quarter last year, the company posted ($0.74) earnings per share. View Audentes Therapeutics' Earnings History.

When is Audentes Therapeutics' next earnings date?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Audentes Therapeutics.

What price target have analysts set for BOLD?

15 equities research analysts have issued 12-month price targets for Audentes Therapeutics' stock. Their predictions range from $20.00 to $57.00. On average, they expect Audentes Therapeutics' stock price to reach $39.9931 in the next year. This suggests a possible upside of 3.1% from the stock's current price. View Analyst Price Targets for Audentes Therapeutics.

What is the consensus analysts' recommendation for Audentes Therapeutics?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Audentes Therapeutics.

What are Wall Street analysts saying about Audentes Therapeutics stock?

Here are some recent quotes from research analysts about Audentes Therapeutics stock:
  • 1. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (7/10/2019)
  • 2. HC Wainwright analysts commented, "Our $44 (raised from $33) price target on shares of Audentes is based on a 12-year DCF-based, sum-of-the-parts analysis, which includes AT132 being developed for XLMTM and AT845, that is being advanced as a one-and-done approach for Pompe disease. Note, our prior $33 target, did not reflect AT-845. Our DCF is driven by a: beta of 1.25, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.0%, and tax rate of 15% beginning in FY 2028." (3/18/2019)
  • 3. Mizuho analysts commented, "We spoke with management following yesterday’s regulatory update on AT132. Audentes held an encouraging first meeting with regulators and will continue to enroll patients in the high-dose cohort 2. Six-month biopsy data from this high- dose cohort is expected in 2Q19 and will help inform an optimal dose of AT132. Audentes then plans to submit an updated data package to the FDA, after which a second FDA meeting will be held; we anticipate this could happen in 3Q19 and we expect minutes from this meeting will provide more clarity around the pathway to a BLA filing for AT132. This could be an important catalyst in 2019. In the meantime, the next data update will be ASGCT." (2/1/2019)

Has Audentes Therapeutics been receiving favorable news coverage?

Media headlines about BOLD stock have trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Audentes Therapeutics earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Audentes Therapeutics.

Who are some of Audentes Therapeutics' key competitors?

What other stocks do shareholders of Audentes Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer LP Unit (ET), Exelixis (EXEL), Global Blood Therapeutics (GBT), Gilead Sciences (GILD), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Intel (INTC), Myriad Genetics (MYGN), Ford Motor (F) and Amicus Therapeutics (FOLD).

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:
  • Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 47)
  • Ms. Natalie C. Holles, Pres & COO (Age 46)
  • Mr. Thomas P. Soloway, Exec. VP & CFO (Age 52)
  • Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 56)
  • Mr. Andrew H. Chang, Director of Investor Relations

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an IPO on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Audentes Therapeutics' major shareholders?

Audentes Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Versant Venture Management LLC (1.25%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Audentes Therapeutics stock include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics.

Which major investors are selling Audentes Therapeutics stock?

BOLD stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC. Company insiders that have sold Audentes Therapeutics company stock in the last year include John T Gray, Louis G Lange, Matthew R Patterson and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.

Which major investors are buying Audentes Therapeutics stock?

BOLD stock was purchased by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. View Insider Buying and Selling for Audentes Therapeutics.

How do I buy shares of Audentes Therapeutics?

Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $38.80.

How big of a company is Audentes Therapeutics?

Audentes Therapeutics has a market capitalization of $1.72 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe.View Additional Information About Audentes Therapeutics.

What is Audentes Therapeutics' official website?

The official website for Audentes Therapeutics is http://www.audentestx.com/.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]


MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  340 (Thanks for Voting!)
Underperform Votes:  297 (Thanks for Voting!)
Total Votes:  637
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2019 by MarketBeat.com Staff

Featured Article: What causes a recession?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel